Heterocyclylalkylamines as muscarinic receptor antagonists

Details Heterocyclylalkylamines as muscarinic receptor antagonists Heterocyclylalkylamines as muscarinic receptor antagonists

2001-05-22

2003-12-23

Rao, Deepak (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S212030, C514S218000, C540S488000, C540S492000, C540S531000

Reexamination Certificate

active

06667301

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to heterocyclylalkylamine derivatives, associated pharmaceutically acceptable salts, or hydrates thereof, and associated pharmaceutical compositions and methods for use as a M2/M3 selective muscarinic receptor antagonists.
BACKGROUND OF THE INVENTION
Acetylcholine (Ach) is the principal transmitter of the parasympathetic nervous system. The physiological actions of Ach are mediated by activation of either nicotinic or muscarinic receptors. Both of these receptor classes are heterogeneous: e.g., the muscarinic receptor family comprises five subtypes (M
1
, M
2
, M
3
, M
4
, and M
5
) each encoded by distinct genes and possessing unique pharmacology and distribution.
Almost all smooth muscle tissues express both muscarinic M2 and M3 receptors, both of which have a functional role. M2 receptors outnumber M3 receptors by a proportion of approximately 4 to 1. Generally, M3 receptors mediate the direct contractile effects of acetylcholine in the vast majority of smooth muscle tissues. M2 receptors, on the other hand, cause smooth muscle contraction indirectly by inhibiting sympathetically (&bgr;-adrenoreceptor)-mediated relaxation.
Compounds that act as antagonists of muscarinic receptors have been used to treat several disease states associated with improper smooth muscle function. Until recently, most of these compounds have been non-selective for the various muscarinic receptor subtypes, leading to unpleasant anti-cholinergic side-effects such as dry mouth, constipation, blurred vision, or tachycardia. The most common of these side-effects is dry-mouth resulting from muscarinic receptor blockade in the salivary gland. Recently developed M2 or M3 specific antagonists have been shown to have reduced side effects. Evidence suggests that concurrent blockade of M2 and M3 receptors could be therapeutically effective in the treatment of disease states associated with smooth muscle disorders.
Few M2/M3 selective antagonists have been developed. The present invention fills this need by providing these types of antagonists useful in the treatment of disease states associated with improper smooth muscle function.
SUMMARY OF THE INVENTION
This invention relates to compounds comprising Formula I:
wherein:
R
1
, R
2
and R
3
are independently in each occurrence hydrogen, halogen, (C
16
)-alkyl, —OR′, —SR′, —NR′R″, —SOR′, —SO
2
R′, —COOR′, —OCOR′, —OCONR′R″, —OSO
2
R′, —OSO
2
NR′R″; —NR′SO
2
R″, —NR′COR″, —SO
2
NR′R″, —SO
2
(CH
2
)
1-3
CONR′R″, —CONR′R″, cyano, haloalkyl, or nitro; or R
1
and R
2
if adjacent, taken together with the carbons to which they are attached may also form a 5- to 7-membered aromatic, saturated or unsaturated ring, optionally incorporating one or two ring heteroatoms chosen from N, S (O)
0-2
, or O, and optionally substituted with (C
1-6
)-alkyl, halo, cyano or lower alkoxy;
R′ and R″ are independently in each occurrence hydrogen, (C
1-6
)-alkyl, substituted lower alkyl, (C
0-3
)alkylalkoxy, aryl, heterocyclyl, heteroaryl, aryl-(C
1-3
)-alkyl, heteroaryl-(C
1-3
)-alkyl, heterocyclyl-(C
1-3
)-alkyl, cycloalkylalkyl, cycloalkyl, or R′ and R″ together with the nitrogen they are attached may also form a 5- to 7-membered ring, optionally incorporating one additional ring heteroatom chosen from N, O or S(O)
0-2
;
R
4
is independently in each occurrence (C
1-6
) alkyl;
R
5
is independently in each occurrence (C
1-6
) alkyl, (C
1-6
) alkenyl, (C
1-6
) alkynyl, or cycloalkyl;
one of X, Y or Z is independently S, O, CH
2
or N—R
6
, the others are CH
2
;
R
6
is hydrogen, (C
1-6
)-alkyl, haloalkyl, aryl(C
1-6
)alkyl, heteroaryl(C
1-6
)alkyl, —(C
1-6
)—CR′R′R′, —COOR′, —SO
2
R′, —C(O)R′, —SO
2
(CH
2
)
0-3
NR′R″, —CONR′R″, —C(O)OCH
2
OC(O)R′, —C(O)OCH
2
SC(O)R′, or —PO(OR′)
2
, where R′ and R″ are as defined above;
m is an integer from 0 to 3 inclusive;
n is an integer from 1 to 6 inclusive;
and prodrugs, individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof.
In a preferred embodiment n is 3; and in another preferred embodiment n is 3 and R
4
is methyl.
In a preferred embodiment, R
4
is methyl, in another preferred embodiment R
4
is methyl and m is 0.
In another preferred embodiment, R
4
is methyl and m is 1, and in another preferred embodiment, R
4
is methyl, m is 1 and Y is NH.
In another preferred embodiment, R
4
is methyl and m is 2, in another preferred embodiment R
4
is methyl, m is 2, and one of X, Y, or Z is NR
6
and the others are CH
2
, and in another preferred embodiment R
4
is methyl, m is 2, and X is NH. In another preferred embodiment, R
4
is methyl, m is 2, and Y is NH, and in another preferred embodiment, R
4
is methyl, m is 2, and Z is NH.
In another preferred embodiment R
4
is methyl, m is 2, and one of X, Y, or Z is NR
6
and the others are CH
2
, and n is 3.
In another preferred embodiment, R
4
is methyl, m is 2 and one of X, Y, or Z is O.
In another preferred embodiment, R
4
is methyl, m is 2 and one of X, Y, or Z is S.
In a preferred embodiment the compound is 1-(4-{ethyl-[2-(4-methanesulfonylphenyl)-1-methylethyl]amino}butyl)-azepan-2-one; 4-(4-{allyl-[2-(4-methanesulfonylphenyl)-1-methylethyl]amino}butyl)-[1,4]diazepan-5-one; 4-(4-{[2-(4-tert-butylphenyl)-1-methylethyl]propylamino}butyl)-[1,4]diazepan-5-one; 1-(4-{[2-(4-methanesulfonylphenyl)-1-methylethyl]propylamino}butyl)-piperazin-2-one; 4-(4-{[2-(4-methanesulfonylphenyl)-1-methylethyl]propylamino}butyl)-5-oxo-[1,4]diazepane-1-carboxylic acid ethyl ester; 1-(4-{[(S)-2-(-4-methanesulfonyl-phenyl)-1-methylethyl]propylamino}butyl)-[1,4]diazepan-2-one; 4-(4-{[(S)-2-(4-methanesulfonylphenyl)-1-methyl-ethyl]propylamino}butyl)-[1,4]diazepan-5-one; 1-(2-{ethyl-[2-(4-methoxyphenyl)-1-methylethyl]amino}ethyl)-piperidin-2-one; 4-(4-{[2-(4-methanesulfonylphenyl)-1-methylethyl]propylamino}butyl)-[1,4]oxazepan-3-one; 1,1,1-trifluoromethanesulfonic acid 4-(2-{ethyl-[4-(2-oxo-azepan-1-yl)butyl]-amino}propyl)-phenyl ester; or a prodrug, an individual isomer, a racemic or non-racemic mixture of isomers, or pharmaceutically acceptable salt or solvate thereof.
In another aspect the invention relates to pharmaceutical compositions containing a therapeutically effective amount of at least one compound of Formula I, or prodrugs, individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof, in admixture with at least one suitable carrier. In a more preferred embodiment, the pharmaceutical compositions are suitable for administration to a subject having a disease state which is alleviated by treatment with a muscarinic M2/M3 receptor antagonist.
In another aspect the invention relates to methods for treating a subject having a disease state that is alleviated by treatment with a muscarinic M2/M3 receptor antagonist, which comprises administering to such a subject a therapeutically effective amount of at least a compound of Formula I, or prodrugs, individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. In a preferred embodiment, the subject has a disease state comprising smooth muscle disorders; preferably genitourinary tract disorders, respiratory tract disorders, gastrointestinal tract disorders, more preferably genitourinary tract disorders such as overactive bladder or detrusor hyperactivity and its symptoms such as the changes symptomatically manifested as urgency, frequency, reduced bladder capacity, incontinence episodes, and the like; the changes urodynamically mani

Affiliated with

Also associated with

Rating

Heterocyclylalkylamines as muscarinic receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterocyclylalkylamines as muscarinic receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclylalkylamines as muscarinic receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3173772